Clairvoyant Therapeutics Advances Psilocybin Clinical Trial for Alcohol Use Disorder

Clairvoyant Therapeutics Inc., a clinical-stage pharmaceutical company, is advancing in its mission to commercialize a psilocybin treatment for Alcohol Use Disorder (AUD), projecting potential market introduction as early as the second half of 2025. This innovative treatment approach marks a significant milestone towards becoming the world's first clinically validated psilocybin solution for AUD.

The company's Phase 2b clinical trial, named CLA-PSY-201, has successfully administered doses to over 90% of its intended 128 participants across 12 active sites in Canada and Europe, paving the way for a crucial topline data release expected in the third quarter of 2024. Alongside this development, Clairvoyant Therapeutics is conducting a Series A financing round to support its ongoing research and development efforts.

Damian Kettlewell, CEO of Clairvoyant, highlighted the significance of this moment for psilocybin treatment, underpinned by robust safety and efficacy data from previous studies. Conditional marketing authorization in Canada and the European Union could be achieved based on the treatment's potential benefits over existing AUD medications. This authorization would necessitate further studies to validate these initial findings, which Clairvoyant plans to undertake with a pivotal trial anticipated in the second half of 2025.

Committed to patient safety, Clairvoyant ensures participants receive support from trained therapists throughout the treatment process. This focus on therapy adherence and protocol ethics underscores the company's dedication to the well-being of participants and the integrity of the trial.